Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

22.01
Delayed Data
As of 3:59pm ET
 +0.64 / +3.02%
Today’s Change
19.59
Today|||52-Week Range
71.50
-64.47%
Year-to-Date
3 Value Stocks Near 52-Week Lows Worth Buying
1:44pm / MotleyFool.com - Paid Partner Content
Why Ionis Pharmaceuticals Plummeted Today
May 26 / MotleyFool.com - Paid Partner Content
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
11:20am / Zacks.com - Paid Partner Content
3 Stocks Underperforming Today In The Drugs Industry
May 26 / TheStreet.com - Paid Partner Content
Ionis Pharmaceuticals (IONS) Stock Falls, BMO Downgrades on GlaxoSmithKline Trial Del...
9:38am / TheStreet.com - Paid Partner Content
Why Ionis Pharmaceuticals (IONS) Stock Is Tanking Today
May 26 / TheStreet.com - Paid Partner Content
Analysts' Actions -- Deckers, Palo Alto Networks, Signet Jewelers, Workday and More
8:11am / TheStreet.com - Paid Partner Content
Alnylam Rises After Ionis Partner Decides Not To Start Phase 3 Study
May 26 / TheStreet.com - Paid Partner Content
Jim Cramer's 'Mad Money' Recap: Stay Disciplined in This Market
May 26 / TheStreet.com - Paid Partner Content
The Best Stocks for Risk-Tolerant Investors
May 25 / MotleyFool.com - Paid Partner Content
Why Abercrombie & Fitch, Ionis Pharmaceuticals, and Movado Group Slumped Today
May 26 / MotleyFool.com - Paid Partner Content
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Why Alnylam Pharmaceuticals, Inc. Competed Higher Today
May 26 / MotleyFool.com - Paid Partner Content
Drawing Biopharma Concepts With A Crayon
May 23 / MotleyFool.com - Paid Partner Content
Cramer: Avoid Sloppiness by Watching Your Stock Table Manners
May 26 / TheStreet.com - Paid Partner Content